The Food and Drug Administration (FDA) recently announced a pilot program offering expedited priority review vouchers to U.S. companies aligning drug development with national public health priorities. This initiative aims to shrink drug approval timelines from the standard 10 months to as little as one to two months, by allowing submission of significant portions of drug applications before clinical trials conclude. While FDA Commissioner Marty Makary views this as an efficient modernization, critics caution about potential risks such as political influence over voucher allocation and the implications of drastically shortened review periods. The program reflects a broader FDA effort to accelerate drug development while maintaining regulatory oversight.